Department of Neurosurgery and Physiology, University of Texas, Health Science Center, 7703 Floyd Curl Drive-7843, San Antonio, TX 78229-3900, USA.
Expert Opin Biol Ther. 2010 Jun;10(6):937-49. doi: 10.1517/14712598.2010.481435.
Recombinant erythropoietin (rEPO) failed in a recent clinical study to protect from damages induced by ischemic stroke. The lack of acute treatments in ischemic stroke and the promising outcome in numerous preclinical studies in vivo demands a more critical evaluation of the future use of EPO as an acute treatment.
The current use and administration of rhEPO and its analogs in animal models and the future use of this cytokine in the treatment of ischemic stroke.
In this review the potential reasons for the failure of EPO in the clinical trial are analysed and whether the preclinical trials sufficiently evaluated the true potential of recombinant EPO and its analogs is assessed. Alternative methods for administration of EPO to enhance its potential as a neuroprotective drug in ischemic stroke are discussed.
Failure in clinical trial does not necessarily indicate the lack of therapeutic potential of EPO. This review encourages further investigation of the true potential of EPO as a candidate drug for the treatment of ischemic stroke by improved preclinical experimental design and utilization of alternative administration methods.
重组红细胞生成素（rEPO）未能在最近的一项临床研究中保护免受缺血性中风引起的损伤。缺血性中风缺乏急性治疗方法，以及在体内大量临床前研究中令人鼓舞的结果，这要求更严格地评估 EPO 作为急性治疗的未来用途。
rhEPO 及其类似物在动物模型中的当前用途和给药方式，以及这种细胞因子在治疗缺血性中风中的未来用途。
在这篇综述中，分析了 EPO 在临床试验中失败的潜在原因，以及临床前试验是否充分评估了重组 EPO 及其类似物的真正潜力。还讨论了 EPO 给药的替代方法，以增强其在缺血性中风中作为神经保护药物的潜力。
临床试验的失败并不一定表明 EPO 缺乏治疗潜力。这篇综述通过改进临床前实验设计和利用替代给药方法，鼓励进一步研究 EPO 作为缺血性中风候选药物的真正潜力。
